Puerarin 6''-O-xyloside (Isoflavone)

Puerarin 6''-O-xyloside is an isoflavone glycoside derived from kudzu root that exhibits bone-protective and anti-cancer properties. This compound works by activating mitochondrial apoptotic pathways through caspase enzyme cascades and modulating cellular death mechanisms.

Origin & History

Puerarin 6''-O-xyloside is a glycosylated isoflavone isolated from the roots of Pueraria lobata (Willd.), a plant used in traditional Chinese medicine. This compound features a puerarin core linked to a xylosyl-glucose moiety via a unique 6''-O-xylosyl glycosidic bond, with a molecular weight of 548.49 g/mol. It is commercially available as a powder with >98% purity, soluble in DMSO.

Historical & Cultural Context

While puerarin 6''-O-xyloside itself has no documented traditional use, it is isolated from Pueraria lobata roots, which have been used in traditional Chinese medicine. The specific historical applications and duration of use for this particular compound are not described in available sources.

Health Benefits

• Anti-osteoporotic effects demonstrated in ovariectomized mice models (preliminary evidence only)
• Anti-tumor activity through induction of mitochondria-mediated cell death (in vitro evidence only)
• Potential regulation of apoptotic pathways involving caspase-3, -7, and -9 activation (mechanistic studies only)
• Possible modulation of Bcl-2/Bax ratio favoring programmed cell death (laboratory evidence only)
• Theoretical activity against various enzyme classes including oxidoreductases and matrix metalloproteinases (computational predictions only)

How It Works

Puerarin 6''-O-xyloside activates the intrinsic apoptotic pathway by triggering mitochondrial membrane permeabilization and subsequent release of cytochrome c. This leads to activation of caspase-3, caspase-7, and caspase-9 enzymes, promoting selective tumor cell death. The compound also appears to modulate osteoblast and osteoclast activity, though the specific bone metabolism pathways remain under investigation.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses have been conducted on puerarin 6''-O-xyloside. Current evidence is limited to preclinical studies in cell cultures and animal models, with no PubMed PMIDs provided in available sources.

Clinical Summary

Current evidence is limited to preclinical studies with no human clinical trials available. In vitro studies demonstrate anti-tumor effects against various cancer cell lines with IC50 values ranging from 25-100 μM depending on cell type. Animal studies using ovariectomized mice showed improved bone mineral density at doses of 50-100 mg/kg body weight over 8-12 week treatment periods. The preliminary nature of this research means clinical efficacy and optimal dosing in humans remain unknown.

Nutritional Profile

Puerarin 6''-O-xyloside is a pure isoflavone glycoside compound (C₂₆H₂₈O₁₃, molecular weight ~552.49 g/mol), not a food ingredient, and therefore carries no conventional macronutrient or micronutrient profile. It is a C-glycoside flavonoid derivative of puerarin (puerarin itself being 8-C-glucosyl daidzein), with an additional xylose sugar unit attached at the 6''-position of the glucose moiety. Bioactive compound content is 100% as an isolated phytochemical. It is naturally found in the root of Pueraria lobata (kudzu root) alongside related isoflavones including puerarin (~1–2% dry weight of kudzu root), daidzin, and daidzein, though Puerarin 6''-O-xyloside itself occurs at considerably lower concentrations than puerarin in the parent plant. As an isoflavone, it contains a phenolic backbone with demonstrated affinity for estrogen receptor beta (ERβ). Bioavailability data specific to this glycoside is very limited; however, C-glycoside isoflavones as a class show relatively poor intestinal absorption compared to aglycones, as they resist hydrolysis by intestinal lactase-phlorizin hydrolase and require colonic microbial metabolism for partial deglycosylation. The additional xylose moiety likely further reduces absorption efficiency relative to puerarin itself. No fiber, protein, fat, vitamins, or mineral content is applicable to this isolated compound.

Preparation & Dosage

No clinically studied dosage ranges are available as human trials have not been conducted. No information on standardized forms, extracts, or recommended doses exists in the scientific literature. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other kudzu isoflavones, puerarin, daidzein, genistein, quercetin

Safety & Interactions

No human safety data exists for puerarin 6''-O-xyloside specifically, though related puerarin compounds are generally well-tolerated. Potential interactions with estrogen-based medications are theoretically possible due to isoflavone activity. Pregnant and breastfeeding women should avoid use due to lack of safety data and potential hormonal effects. As with other isoflavones, individuals with hormone-sensitive conditions should consult healthcare providers before use.